CHELSEA JOHNSON: Open Payments
NPI 1194489575 · GRAND ISLAND, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,587 in 118 payments from 11 companies in 2025. Trend: 2023 $1,535 · 2024 $803 · 2025 $1,587
Food & beverage: $1,587
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 18 | $283 |
| ABBVIE INC. | 30 | $261 |
| Teva Pharmaceuticals USA, Inc. | 19 | $230 |
| Alkermes, Inc. | 13 | $149 |
| Axsome Therapeutics, Inc. | 4 | $148 |
| E.R. Squibb & Sons, L.L.C. | 15 | $142 |
| Neurocrine BioSciences, Inc. | 7 | $126 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $113 |
| CSL Behring | 2 | $65 |
| Janssen Pharmaceuticals, Inc | 3 | $56 |
Products named: VRAYLAR, REXULTI, ARISTADA, Auvelity, COBENFY, AUSTEDO XR, INGREZZA, ABILIFY MAINTENA.
Industry payments across NE — which companies pay providers there.
